Emcure Pharmaceuticals Management Change
Emcure Pharmaceuticals announced a board reorganization. Mr. Raghu Kumar was appointed as Additional Independent Director, while Mr. Satish Mehta will become Chairman following Mr. Berjis Desai's retirement.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
Emcure Pharmaceuticals announced a board reorganization. Mr. Raghu Kumar was appointed as Additional Independent Director, while Mr. Satish Mehta will become Chairman following Mr. Berjis Desai's retirement.
Mr. P.S. Jayakumar has ceased to be an Independent Director of Emcure Pharmaceuticals Limited effective July 21, 2026, following the completion of his second consecutive term.
Mr. Kuber Jagdale, President - API Business, superannuated from Emcure Pharmaceuticals on June 30, 2026. This resulted in a change of senior management.
Emcure Pharmaceuticals approved the re-appointment of Mr. Satish Mehta as MD for five years starting April 2027 and Mr. Mukund Gurjar as Executive Director for twelve months starting August 2026. The appointments were approved during the board meeting held on May 5, 2026, ensuring leadership continuity for the company.
Emcure Pharmaceuticals approved the re-appointment of Dr. Mukund Gurjar as Whole-time Director for one year and Mr. Satish Mehta as Managing Director for five years. The board meeting concluded on May 05, 2026. These leadership continuations aim to ensure management stability for the company's long-term growth plans.
Emcure Pharmaceuticals approved the re-appointment of Dr. Mukund Gurjar as Whole-time Director for one year and Mr. Satish Mehta as Managing Director for five years. These leadership extensions remain subject to shareholder approval.